Compare CKX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | AKTX |
|---|---|---|
| Founded | 1930 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 18.2M |
| IPO Year | 1996 | 2014 |
| Metric | CKX | AKTX |
|---|---|---|
| Price | $11.06 | $9.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 10.2K | ★ 81.5K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1125.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $838,543.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $368.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $0.12 |
| 52 Week High | $13.00 | $29.32 |
| Indicator | CKX | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 46.71 |
| Support Level | $11.03 | $0.32 |
| Resistance Level | $11.76 | $29.32 |
| Average True Range (ATR) | 0.60 | 1.66 |
| MACD | -0.04 | -0.52 |
| Stochastic Oscillator | 33.60 | 18.56 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way, and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. It has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Timber segment.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.